Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS

Keyphrases

• Cyclic GMP 100%
• NO-cGMP 100%
• Translational Potential 100%
• PDE5 Inhibitors 66%
• Human Disease 33%
• Signaling Molecules 33%
• Clinical Evaluation 33%
• First-in-class 33%
• Therapeutic Targeting 33%
• Molecular Events 33%
• Endotoxic Shock 33%
• Downstream Signaling 33%
• Diabetic Cardiomyopathy 33%
• Pulmonary Hypertension 33%
• Haem 33%
• Cardiovascular Effects 33%
• Prosthetic Group 33%
• Myocardial Failure 33%
• Complex Pathways 33%
• Organic Nitrates 33%
• Erectile Dysfunction 33%
• Becker muscular Dystrophy 33%
• Nobel Prize 33%
• Experimental Disease Models 33%
• Novel Indications 33%
• Well-founded 33%

Medicine and Dentistry

• Cyclic GMP 100%
• Phosphodiesterase V Inhibitor 50%
• Clinical Trial 25%
• Medicine 25%
• Rehabilitation Engineering 25%
• Mediator 25%
• Heme 25%
• Septic Shock 25%
• Signaling Molecule 25%
• Diabetic Cardiomyopathy 25%
• Pulmonary Hypertension 25%
• Congestive Heart Failure 25%
• Cardiovascular Effect 25%
• Disease Model 25%
• Erectile Dysfunction 25%
• Organic Nitrate 25%
• Experimental Disease 25%
• Becker Muscular Dystrophy 25%
• Diseases 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Cyclic GMP 100%
• Phosphodiesterase V Inhibitor 50%
• Clinical Trial 25%
• Congestive Heart Failure 25%
• Septic Shock 25%
• Disease Model 25%
• Diabetic Cardiomyopathy 25%
• Heme 25%
• Pulmonary Hypertension 25%
• Experimental Disease 25%
• Organic Nitrate 25%
• Erectile Dysfunction 25%
• Becker Muscular Dystrophy 25%
• Diseases 25%